BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20666024)

  • 1. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
    Watson AP; Egland KA
    S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers in breast cancer prognosis and treatment.
    Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH
    J BUON; 2010; 15(3):447-54. PubMed ID: 20941809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of prostate-specific antigen (PSA) in cytosol of breast tumors and human endometrium--new diagnostic approaches].
    Seliger E; Kaltwasser P; Röpke F
    Zentralbl Gynakol; 1998; 120(4):172-5. PubMed ID: 9610520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer biomarkers: knowing the present and predicting the future.
    Chatterjee SK; Zetter BR
    Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.
    Sauter ER; Daly M; Linahan K; Ehya H; Engstrom PF; Bonney G; Ross EA; Yu H; Diamandis E
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):967-70. PubMed ID: 8959318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
    Bickers B; Aukim-Hastie C
    Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen value as a marker in breast cancer.
    Narita D; Cimpean AM; Anghel A; Raica M
    Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Dowsett M; Dunbier AK
    Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer.
    Heyl W; Wolff JM; Biesterfeld S; Schröder W; Zitzelsberger D; Jakse G; Rath W
    Anticancer Res; 1999; 19(4A):2563-5. PubMed ID: 10470195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
    Fradet Y
    Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for prostate cancer detection.
    Reed AB; Parekh DJ
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):103-14. PubMed ID: 20014890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.
    Reuben JM; Lee BN; Li C; Gao H; Broglio KR; Valero V; Jackson SA; Ueno NT; Krishnamurthy S; Hortobagyi GN; Cristofanilli M
    Breast J; 2010; 16(3):327-30. PubMed ID: 20408820
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen may serve as a pathological predictor in breast cancer.
    Nariţa D; Anghel A; Motoc M
    Rom J Morphol Embryol; 2008; 49(2):173-80. PubMed ID: 18516323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.
    Fuqua SA; Cui Y
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S3-10. PubMed ID: 15597215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.